- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Tevogen Bio Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Mi | Tevogen Bio becomes Tevogen Inc. | 4 | Seeking Alpha | ||
| 14.07. | Tevogen Bio Inc: Tevogen Bio Announces 2026 Annual Meeting of Stockholders | 1 | GlobeNewswire (USA) | ||
| TEVOGEN Aktie jetzt für 0€ handeln | |||||
| 10.07. | Tevogen Bio Holdings Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 09.06. | Tevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services Initiative | 591 | GlobeNewswire (Europe) | William Keane Appointed Interim Head of Initiative, Evaluating Potential Management Services Organization and Contract Research Organization Acquisitions WARREN, N.J., June 09, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 28.05. | Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue | 621 | GlobeNewswire (Europe) | WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced continued progress across its strategic acquisition initiatives intended... ► Artikel lesen | |
| 21.05. | Tevogen Bio Inc: Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization | 503 | GlobeNewswire (Europe) | WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter... ► Artikel lesen | |
| 20.05. | Tevogen Bio Holdings reports Q1 results; operating loss falls 48% | 3 | Seeking Alpha | ||
| 18.05. | Tevogen reports reduced operating losses in 2025 and Q1 2026 | 1 | Investing.com | ||
| 18.05. | Tevogen Bio Inc: Letter to Shareholders from CEO Dr. Ryan Saadi | 141 | GlobeNewswire (Europe) | WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN). Dear Shareholders, Since Tevogen's 2024 public listing, we have remained focused on... ► Artikel lesen | |
| 15.05. | Tevogen Bio Holdings Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | Tevogen Bio Inc: Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close | 304 | GlobeNewswire (Europe) | WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a securities purchase agreement for a private... ► Artikel lesen | |
| 30.04. | Tevogen Bio Holdings Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 22.04. | Tevogen Bio Holdings Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Tevogen Bio Holdings Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 26.03. | Tevogen Bio Inc: Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth | 348 | GlobeNewswire (Europe) | Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devicesTarget CRO operates... ► Artikel lesen | |
| 25.03. | Tevogen Bio erfüllt nach Aktienzusammenlegung wieder Nasdaq-Anforderungen | 3 | Investing.com Deutsch | ||
| 25.03. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.03. | Tevogen Bio Inc: Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement | 253 | GlobeNewswire (Europe) | WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) received written notice (the "Notification Letter") from The Nasdaq Stock Market... ► Artikel lesen | |
| 13.03. | Tevogen Bio Inc: Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization | 424 | GlobeNewswire (Europe) | Lead investor confirmed his intention to maintain his current shareholdings.Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next... ► Artikel lesen |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,990 | -2,55 % | PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
QIAGEN N.V.: Veröffentlichung nach -- 40 Abs. 1 WpHG
Venlo (pta000/29.07.2026/22:05... ► Artikel lesen | |
| VALNEVA | 2,184 | +0,55 % | Valneva ÜBERRASCHT Anleger: Die Entwicklung die jetzt niemand auf dem Schirm hat - Jetzt nicht wegschauen | ||
| AMGEN | 334,55 | -0,51 % | Kleinzelliges Lungenkarzinom (SCLC): Hoch aggressiv und schwer behandelbar / Biotechnologieunternehmen Amgen engagiert sich in der Erforschung neuer Therapieansätze | München (ots) - Das kleinzellige Lungenkarzinom (Small Cell Lung Cancer, SCLC) ist eine der aggressivsten Formen von Lungenkrebs. Die Erkrankung schreitet besonders schnell voran, streut früh in andere... ► Artikel lesen | |
| NOVAVAX | 6,470 | +0,15 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 7,870 | +0,38 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 620,70 | -3,05 % | Regeneron Pharmaceuticals Inc Bottom Line Retreats In Q2 | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc (REGN) revealed a profit for second quarter that Drops, from the same period last yearThe company's earnings totaled $1.296 billion, or $12.23... ► Artikel lesen | |
| VIVOSIM LABS | 0,376 | -2,51 % | VivoSim Labs, INC. - 8-K, Current Report | ||
| INOVIO PHARMACEUTICALS | 0,554 | -3,06 % | Inovio Pharmaceuticals, Inc.: INOVIO Announces Pricing of $20.0 Million Public Offering | PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 4,810 | +4,34 % | COSCIENS Biopharma Inc. Completes Share Capital Amendment | TORONTO, ONTARIO, July 03, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company"), today announced the previously announced consolidation (the "Consolidation")... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,150 | +0,44 % | Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026 | Vivoryon Therapeutics N.V. to Report H1 2026 Financial Resultsand Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026
Halle (Saale) / Munich, Germany, July... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 53,70 | -1,03 % | H.C. Wainwright reiterates BioMarin stock rating at Neutral | ||
| SAREPTA THERAPEUTICS | 13,360 | -1,04 % | Sarepta Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| ARROWHEAD PHARMACEUTICALS | 74,86 | -1,11 % | H.C. Wainwright raises Arrowhead Pharma price target to $115 on trial data | ||
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| PHIO PHARMACEUTICALS | 1,040 | +0,97 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series | King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary... ► Artikel lesen |
TEVOGEN INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +7,14 % bei einem Aktienkurs von 7,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN INC finden Sie auf Wallstreet Online.